Want to see PRCT full AI Analyst Report?
PRCT Stock Chart & Stats
$21.60
$1.00(5.99%)
At close: 4:00 PM EDT
$21.60
$1.00(5.99%)
Day’s Range― - ―
52-Week Range$16.67 - $38.11
Previous Close$18
Volume1.34M
Average Volume (3M)1.37M
Market Cap
$1.05B
Enterprise Value$1.14B
Total Cash (Recent Filing)$227.91M
Total Debt (Recent Filing)$77.50M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Nov 04, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding57,273,660
10 Day Avg. Volume1,347,530
30 Day Avg. Volume1,373,892
Financial Highlights & Ratios
PEG Ratio10.67
Price to Book (P/B)4.78
Price to Sales (P/S)5.67
P/FCF Ratio-29.95
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue3.37
Enterprise Value/Gross Profit5.29
Enterprise Value/Ebitda-11.50
Forecast
1Y Price Target
$22.89Price Target Upside5.97% Upside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)-1.67
Revenue Forecast (FY)$395.29M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue has expanded dramatically over several years, indicating growing adoption of PROCEPT’s platform and a sizable commercial opportunity. Continued top-line momentum can support operating leverage, broaden the installed base, and provide a foundation for improving profitability as utilization increases.
HYDROS Adoption And PricingStrong HYDROS placements combined with record system pricing suggest customers are validating the platform’s clinical and economic value. A growing installed base can generate recurring procedure-related consumables revenue, while pricing strength supports revenue quality and future gross-margin durability.
Clinical And Regulatory SupportClinical evidence, professional-society support, and continued regulatory progress can strengthen physician confidence and expand adoption of Aquablation. These milestones improve the platform’s credibility over time and may support broader use across hospitals and surgical centers.
Bears Say
Persistent Cash BurnHeavy and worsening cash consumption leaves the company dependent on its cash balance and future financing or operating improvement. Until losses narrow, ongoing investment in commercialization and research may reduce financial flexibility and increase the consequences of execution setbacks.
Legacy AQUABEAM WeaknessWeakness in the legacy installed base can suppress procedure-driven consumables revenue even while HYDROS adoption grows. Because AQUABEAM and HYDROS accounts remain roughly split, unresolved utilization issues could weigh on near-term growth and complicate the transition to the newer platform.
Ongoing UnprofitabilityThe company has not yet converted strong revenue growth into sustainable earnings, as operating costs remain high and losses are substantial. Continued spending is necessary to scale the platform, but it delays self-funded growth and leaves results sensitive to slower adoption or weaker procedure utilization.
PROCEPT BioRobotics News
PRCT FAQ
What was PROCEPT BioRobotics’s price range in the past 12 months?
PROCEPT BioRobotics lowest stock price was $16.66 and its highest was $38.11 in the past 12 months.
What is PROCEPT BioRobotics’s market cap?
PROCEPT BioRobotics’s market cap is $1.05B.
When is PROCEPT BioRobotics’s upcoming earnings report date?
PROCEPT BioRobotics’s upcoming earnings report date is Nov 04, 2026 which is in 12 days.
How were PROCEPT BioRobotics’s earnings last quarter?
PROCEPT BioRobotics released its earnings results on Aug 04, 2026. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.462 by -$0.008.
Is PROCEPT BioRobotics overvalued?
According to Wall Street analysts PROCEPT BioRobotics’s price is currently Undervalued.
Does PROCEPT BioRobotics pay dividends?
PROCEPT BioRobotics does not currently pay dividends.
What is PROCEPT BioRobotics’s EPS estimate?
PROCEPT BioRobotics’s EPS estimate is -0.39.
How many shares outstanding does PROCEPT BioRobotics have?
PROCEPT BioRobotics has 57,273,660 shares outstanding.
What happened to PROCEPT BioRobotics’s price movement after its last earnings report?
PROCEPT BioRobotics reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.462. Following the earnings report the stock price went up 5.799%.
Which hedge fund is a major shareholder of PROCEPT BioRobotics?
Currently, no hedge funds are holding shares in PRCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PROCEPT BioRobotics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$22.89 (5.97% Upside)
$22.89 (5.97% Upside)
Blogger Sentiment
Bullish
PRCT Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 14.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $476.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.21%
12-Months-Change
Fundamentals
Return on Equity
-30.62%
Trailing 12-Months
Asset Growth
-6.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
PROCEPT BioRobotics
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
PRCT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally positive outlook driven by strong HYDROS adoption, record pricing, solid top-line growth (Q2 revenue +19% and procedures +21% YoY), important clinical and regulatory milestones, and a clear path to positive adjusted EBITDA in Q4 2026. Offsetting risks include a concentrated procedure shortfall in legacy AQUABEAM accounts, higher operating expenses that widened losses in the quarter, and some one-time benefits (tariff recovery) supporting margins. Management is focused on upgrades, scaling launch teams, and patient-activation initiatives to drive durable utilization improvements.View all PRCT earnings summariesPRCT Stock 12 Month Forecast
Average Price Target
$22.89
▲(5.97% Upside)
Technical Analysis
Ownership Overview
3.35% Insiders
22.34% Mutual Funds
0.57% Other Institutional Investors
56.46% Public Companies and
Individual Investors